8-K: Matinas BioPharma Implements 1-for-50 Reverse Stock Split and Reduces Authorized Shares

Matinas BioPharma has executed a 1-for-50 reverse stock split and reduced its authorized shares from 500 million to 250 million, effective August 30, 2024.

Summary

• Matinas BioPharma Holdings, Inc. has completed a 1-for-50 reverse stock split of its common stock.
• The reverse stock split was effective at 5:00 PM Eastern Time on August 30, 2024.
• The company also reduced the total number of authorized common shares from 500 million to 250 million.
• The CUSIP number for the common stock has changed to 576810 303.
• Trading on a split-adjusted basis is expected to begin on September 3, 2024, subject to NYSE American approval.
• The company's stock was previously halted on August 27, 2024, due to its low trading price.
• The NYSE American could maintain the trading halt or delist the stock if the post-split price does not meet requirements.
• No fractional shares were issued; instead, shareholders received additional fractions to round up to the next whole share.
• The reverse stock split did not change the par value of the common stock.
• All outstanding securities, such as options and warrants, were adjusted accordingly.

Sentiment

Score: 3

Explanation: The document indicates a negative situation requiring a reverse stock split to avoid delisting, suggesting underlying financial challenges. The sentiment is negative due to the need for this action.

Positives

• The reverse stock split is intended to increase the per-share price of the common stock, potentially avoiding delisting.
• The reduction in authorized shares may signal a more focused capital structure.

Negatives

• The reverse stock split was necessary due to the low trading price of the company's stock.
• The NYSE American could maintain the trading halt or delist the stock if the post-split price does not meet requirements.
• The stock was halted on August 27, 2024, due to its low trading price.

Risks

• The NYSE American may not approve the resumption of trading on a split-adjusted basis.
• The company faces the risk of delisting if the post-split share price does not meet exchange requirements.
• The reverse stock split could negatively impact investor sentiment.

Future Outlook

The company anticipates that the common stock will begin trading on the NYSE American on a reverse stock split-adjusted basis when the market opens on September 3, 2024, subject to exchange approval. However, the exchange could maintain the trading halt or delist the stock if the price per share post-split does not meet the requirements.

Management Comments

• Jerome D. Jabbour, Chief Executive Officer, signed the report on behalf of the company.

Industry Context

Reverse stock splits are often used by companies to increase their share price and avoid delisting from exchanges. This action is not uncommon for companies facing low stock prices.

Comparison to Industry Standards

• Reverse stock splits are a common mechanism for companies to regain compliance with exchange listing requirements, particularly when facing low share prices.
• Many companies in the biotechnology sector, especially those in the development stage, have used reverse stock splits to maintain their listing status.
• For example, companies like Agenus Inc. and Ocugen Inc. have also recently implemented reverse stock splits to meet minimum price requirements.

Stakeholder Impact

• Shareholders will see a reduction in the number of shares they own, but their percentage ownership remains the same.
• The reverse stock split may impact investor confidence and market perception of the company.
• The company's ability to raise capital may be affected by the reverse stock split.

Next Steps

• The company will seek approval from the NYSE American to resume trading on a split-adjusted basis.
• The company will monitor the stock price to ensure it meets the exchange's minimum requirements.

Key Dates

Keywords

reverse stock split, authorized shares, common stock, NYSE American, delisting, stock halt, Matinas BioPharma, share reduction